- Home
- KNDI vs VTYX Comparison
KNDI vs VTYX Comparison
Compare KNDI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- VTYX
- Stock Information
- Founded
- KNDI 2002
- VTYX 2018
- Country
- KNDI China
- VTYX United States
- Employees
- KNDI N/A
- VTYX N/A
- Industry
- KNDI Auto Manufacturing
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- KNDI Consumer Discretionary
- VTYX Health Care
- Exchange
- KNDI Nasdaq
- VTYX Nasdaq
- Market Cap
- KNDI 154.6M
- VTYX 148.4M
- IPO Year
- KNDI N/A
- VTYX 2021
- Fundamental
- Price
- KNDI $1.25
- VTYX $1.87
- Analyst Decision
- KNDI
- VTYX Buy
- Analyst Count
- KNDI 0
- VTYX 5
- Target Price
- KNDI N/A
- VTYX $8.40
- AVG Volume (30 Days)
- KNDI 168.1K
- VTYX 984.2K
- Earning Date
- KNDI 11-18-2024
- VTYX 11-07-2024
- Dividend Yield
- KNDI N/A
- VTYX N/A
- EPS Growth
- KNDI N/A
- VTYX N/A
- EPS
- KNDI N/A
- VTYX N/A
- Revenue
- KNDI $124,609,232.00
- VTYX N/A
- Revenue This Year
- KNDI N/A
- VTYX N/A
- Revenue Next Year
- KNDI N/A
- VTYX N/A
- P/E Ratio
- KNDI N/A
- VTYX N/A
- Revenue Growth
- KNDI N/A
- VTYX N/A
- 52 Week Low
- KNDI $1.20
- VTYX $1.79
- 52 Week High
- KNDI $3.13
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- KNDI 37.72
- VTYX 33.83
- Support Level
- KNDI $1.20
- VTYX $2.10
- Resistance Level
- KNDI $1.38
- VTYX $2.36
- Average True Range (ATR)
- KNDI 0.10
- VTYX 0.13
- MACD
- KNDI 0.00
- VTYX -0.04
- Stochastic Oscillator
- KNDI 17.86
- VTYX 0.00
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.